Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples

Who May Qualify: - Subjects with known or suspected Barrett's esophagus (BE) (cases) - Patients between the ages of 18-90. - Patients with a BE segment ≥ 1cm in maximal extent endoscopically or suspected BE in medical record. - Histology showing evidence of intestinal metaplasia with or without presence of dysplasia or suspected BE in medical record. - Undergoing clinically indicated endoscopy. - Subjects without known history of BE (controls) - Undergoing clinically indicated diagnostic endoscopy Who Should NOT Join This Trial: - For subjects with or without known evidence of BE (on history or review of medical records) - Pregnant or lactating females. - Patients who are unable to consent. - Patients with current history of uninvestigated dysphagia. - History of eosinophilic esophagitis, achalasia. - Patients on oral anticoagulation including Coumadin, Warfarin. - Patients on antiplatelet agents including Clopidogrel, unless discontinued for three to five days prior to the Cytosponge procedure. - Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for three to five days prior to the Cytosponge procedure. - Patients with history of known esophageal or gastric varices or cirrhosis. - Patients with history of surgical esophageal resection for esophageal carcinoma. - Patients with congenital or acquired bleeding diatheses. - Patients with a history of esophageal squamous dysplasia. - Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment. - Patient has received chemotherapy class drugs or radiation to treat mediastinal or esophageal cancer. Always talk to your doctor about whether this trial is right for you.